⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AMRN News
Amarin Corp Plc
Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
globenewswire.com
AMRN
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
globenewswire.com
AMRN
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
globenewswire.com
AMRN